Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Exercise has been shown to improve numerous physical, psychosocial and clinical outcomes in those diagnosed with cancer.

Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.

We have observed the evolution of spatially fractionated radiotherapy (SFRT) primarily to manage metastatic cancer patients in the palliative care setting. Given recent advances in how SFRT can be delivered, can this therapeutic modality be optimized beyond the palliative care setting?

Updates in the treatment of pediatric neuroblastoma and Wilms Tumor are presented, highlighting recent practice-changing publications and evolving study questions.

Significant advances in systemic treatment options have positively impacted breast cancer survivorship.